Oral Anticoagulants and Risk of Nephropathy

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2015 Apr 28

PMID 25913726

Citations 16

Authors

Vinay Narasimha Krishna

David G Warnock

Nakshatra Saxena

Dana V Rizk

Affiliations

Soon will be listed here.

Abstract

Anticoagulant-related nephropathy, a recently recognized entity, manifests as unexplained acute kidney injury in the setting of excessive anticoagulation with oral agents. Histologic findings in warfarin-related nephropathy include glomerular hemorrhage and renal tubular obstruction by red blood cells. Affected patients are at increased risk of mortality as well as irreversible kidney injury. Patients with chronic kidney disease are particularly vulnerable to this complication. Similar case reports of anticoagulant-related nephropathy have been linked to the more novel oral anticoagulant, dabigatran. Anticoagulant-related nephropathy has been successfully reproduced in rat models. These animal models shed light on the pathogenesis of the disease including the potential role of direct thrombin and protease-activated receptor-1 inhibition. Warfarin and dabigatran also cause an increase in systolic blood pressure in rats, a risk factor for developing nephropathy. This article reviews the current evidence for anticoagulant-related nephropathy and provides data for the suggested possible mechanisms underlying this adverse effect.

Citing Articles

Oral Anticoagulant-Related Nephropathy: A New Cause for an Old Entity.

Valerio P, Soares E, Abrantes C, Gois M, Sousa H, Farinha A Indian J Nephrol. 2025; 35(1):113-114.

PMID: 39872276 PMC: 11763026. DOI: 10.25259/IJN_528_20.

Iwafuchi Y, Ito Y, Imai N, Oyama Y, Narita I Intern Med. 2023; 63(11):1615-1621.

PMID: 37866913 PMC: 11189709. DOI: 10.2169/internalmedicine.2628-23.

Practical approaches to building up a cardiorenal clinic.

de la Espriella R, Marcos M, Ronco C, Banerjee D, Gonzalez M, Gorriz J Clin Kidney J. 2023; 16(5):780-792.

PMID: 37151411 PMC: 10157785. DOI: 10.1093/ckj/sfac258.

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis.

Li W, Zhou Y, Chen S, Zeng D, Zhang H Front Cardiovasc Med. 2022; 9:1005742.

PMID: 36176998 PMC: 9513185. DOI: 10.3389/fcvm.2022.1005742.

Dabigatran-Induced Nephropathy and Gastrointestinal Bleeding and Its Successful Treatment with Idarucizumab: A Case Report.

Marchesini F, Ossato A, Zendrini A, Arginelli F, Zuppini T, Realdon N Hosp Pharm. 2022; 57(2):241-245.

PMID: 35601714 PMC: 9117771. DOI: 10.1177/00185787211016335.

References

Guyatt G, Akl E, Crowther M, Gutterman D, Schuunemann H . Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):7S-47S. PMC: 3278060. DOI: 10.1378/chest.1412S3. View

Providencia R, Grove E, Husted S, Barra S, Boveda S, Morais J . A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res. 2014; 134(6):1253-64. DOI: 10.1016/j.thromres.2014.10.002. View

Patel R, Svistunenko D, Darley-Usmar V, Symons M, Wilson M . Redox cycling of human methaemoglobin by H2O2 yields persistent ferryl iron and protein based radicals. Free Radic Res. 1996; 25(2):117-23. DOI: 10.3109/10715769609149916. View

Leven C, Hudier L, Picard S, Longuet H, Lorcy N, Cam G . [Prospective study of drug-induced interstitial nephritis in eleven French nephrology units]. Presse Med. 2014; 43(11):e369-76. DOI: 10.1016/j.lpm.2014.03.032. View

Homsi E, Janino P, de Faria J . Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int. 2006; 69(8):1385-92. DOI: 10.1038/sj.ki.5000315. View

Brodsky S, Nadasdy T, Rovin B, Satoskar A, Nadasdy G, Wu H . Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011; 80(2):181-9. PMC: 3675881. DOI: 10.1038/ki.2011.44. View

Ware K, Brodsky P, Satoskar A, Nadasdy T, Nadasdy G, Wu H . Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol. 2011; 22(10):1856-62. PMC: 3279947. DOI: 10.1681/ASN.2010101110. View

Maddry J, Amir M, Sessions D, Heard K . Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2012; 31(2):462.e1-2. DOI: 10.1016/j.ajem.2012.08.015. View

Yang E . A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?. Vasc Health Risk Manag. 2014; 10:507-22. PMC: 4149394. DOI: 10.2147/VHRM.S68117. View

10.

Bachellerie B, Ruiz S, Conil J, Crognier L, Seguin T, Georges B . [Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery]. Ann Fr Anesth Reanim. 2014; 33(1):44-6. DOI: 10.1016/j.annfar.2013.11.011. View

11.

Kapoor K, Bekaii-Saab T . Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. Intern Med J. 2008; 38(4):281-3. DOI: 10.1111/j.1445-5994.2008.01646.x. View

12.

Wychowski M, Kouides P . Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012; 46(4):e10. DOI: 10.1345/aph.1Q747. View

13.

Krishnan S, Chawla N, Ezekowitz M, Peixoto A . Warfarin therapy and systolic hypertension in men with atrial fibrillation. Am J Hypertens. 2005; 18(12 Pt 1):1592-9. DOI: 10.1016/j.amjhyper.2005.06.001. View

14.

Limdi N, Limdi M, Cavallari L, Anderson A, Crowley M, Baird M . Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010; 56(5):823-31. PMC: 2963672. DOI: 10.1053/j.ajkd.2010.05.023. View

15.

Ozcan A, Ware K, Calomeni E, Nadasdy T, Forbes R, Satoskar A . 5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy. Am J Nephrol. 2012; 35(4):356-64. PMC: 3487141. DOI: 10.1159/000337918. View

16.

Brodsky S, Satoskar A, Chen J, Nadasdy G, Eagen J, Hamirani M . Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009; 54(6):1121-6. DOI: 10.1053/j.ajkd.2009.04.024. View

17.

Hsu C, Chen W, Sung S . Warfarin-induced leukocytoclastic vasculitis: a case report and review of literature. Intern Med. 2012; 51(6):601-6. DOI: 10.2169/internalmedicine.51.6240. View

18.

Di Maso V, Carraro M, Bevilacqua E, Bucconi S, Artero M, Boscutti G . Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile. Clin Kidney J. 2015; 7(6):605-8. PMC: 4389147. DOI: 10.1093/ckj/sfu112. View

19.

Coughlin S . Protease-activated receptors in vascular biology. Thromb Haemost. 2001; 86(1):298-307. View

20.

Poulsen B, Grove E, Husted S . New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012; 72(13):1739-53. DOI: 10.2165/11635730-000000000-00000. View